logo
Bruins' Mason Lohrei, a $6.4 million contract and that minus-43

Bruins' Mason Lohrei, a $6.4 million contract and that minus-43

New York Times25-06-2025
The number that is difficult not to notice on Mason Lohrei's stat line is minus-43. The NHL may someday classify plus-minus as a statistical fossil from a blurrier era. Until then, it will remain a dubious marker, specifically for a defenseman such as Lohrei, who led the category at the wrong end.
Plus-minus's inaccuracy, however, can be summed up as such: On Monday, the winner of what is informally known as the NHL's green jacket signed a two-year, $6.4 million extension with the Boston Bruins.
Advertisement
In 2024-25, both Jim Montgomery and Joe Sacco thought highly enough of Lohrei's offensive firepower that they regularly deployed the defenseman in late-game situations. Opponents pumped pucks into the Bruins' vacated net on 14 of those occasions, pulling Lohrei's plus-minus deeper into the NHL's trough.
'The Bruins, to their credit, did not use that as the only thing they were thinking about, either. We all understand that,' said Brian Bartlett, Lohrei's agent. 'On paper, it wasn't pretty. But if you dig into it, it wasn't nearly as egregious as it looks.'
According to Bartlett, negotiations began several weeks following the conclusion of the regular season. Both employer and employee concluded a bridge deal was the best solution for the 24-year-old, whose entry-level contract was expiring. It gives the Bruins time to determine who Lohrei can become. Lohrei, in turn, will have two windows in which to re-enter the market: after July 1, 2026, with a year left on the deal, or sometime in 2027 at or near the contract's expiration. In either instance, he could have better numbers with which to make his case. He will remain a restricted free agent after this contract.
'We're still very bullish he's got a lot more growth in his game, both offensively and defensively, to round out as a top-four defenseman,' Bartlett said. 'So we weren't really in a rush to do anything long term unless it was at one of those salary numbers where you kind of jump ahead and project him as that guy already. So in our conversations with Boston, when they didn't feel quite ready to make that long-term, big-dollar commitment, we started focusing on what a bridge would look like.'
Mason Lohrei gets in on the goal scoring!
4-0 🇺🇸@NHLBruins | @usahockey | #MensWorlds pic.twitter.com/wJYHy1Mpby
— NHL Network (@NHLNetwork) May 9, 2025
As for Lohrei's $3.2 million yearly payday, his average annual value follows the bridge-deal template of Evan Bouchard ($3.9 million), the Edmonton Oilers' offensive defenseman with a first-round pedigree.
One of the differences is that Bouchard had two 40-plus-point seasons on his resume before he signed his two-year, $7.8 million second contract. In comparison, 2024-25 was Lohrei's first full NHL season. It's harder to say with Lohrei, then, whether his five-goal, 33-point output represents an initial foothold toward an offensive ascent or more of a baseline of what he will become. Lohrei's next step will be to gain new coach Marco Sturm's trust with stouter play in the defensive zone so he can earn more offensive opportunities.
Advertisement
'I want to be a guy that plays in every single situation,' Lohrei said Tuesday following a training session at Culver Military Academy, his former prep school before he advanced to the USHL. 'I know I can get there. It's just about putting in the work and continuing to learn and grow. I want to start games, finish games, play against the other teams' top players, play a lot of minutes, power play, penalty kill, all that stuff. That's what I want to be.'
Lohrei averaged 19:32 of ice time per game. It was probably more than the Bruins expected him to log. But Lohrei took on extra shifts after Hampus Lindholm suffered a season-ending patella injury on Nov. 12. The 2020 second-rounder became a first-unit PP fixture partly because of Charlie McAvoy's shoulder injury and infection at the 4 Nations Face-Off.
In particular, Lohrei had to assume more matchup assignments than the Bruins would have preferred. The Bruins allowed 2.65 expected goals per 60 minutes of five-on-five play, per Natural Stat Trick, with Lohrei on the ice. It was the highest xGA per 60 of any team defenseman.
Sturm will have options. He could use Lohrei on the No. 1 pair with McAvoy. If Sturm prefers a shutdown tandem with McAvoy and Nikita Zadorov, he could roll Lohrei on the No. 3 duo. In any case, Lohrei projects to play less than Lindholm and Zadorov, who are better equipped for matchup duty. Lohrei's strengths lean toward offense.
'What the market looked like last year might be very different from what it looks like in two years,' Bartlett said. 'That's a risk we're willing to take based on Mason's faith in himself and our faith in him. The communication with the Bruins is if Mason turns into that guy we all hope that he does, they'll also be happy to pay him whatever the market rate is at that point.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Red Sox Need This Trade Upgrade For Second Consecutive Season
Why Red Sox Need This Trade Upgrade For Second Consecutive Season

Newsweek

time21 minutes ago

  • Newsweek

Why Red Sox Need This Trade Upgrade For Second Consecutive Season

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Boston Red Sox are in position to buy at the MLB trade deadline despite a 2-4 slump against top talent coming out of the All-Star break. A frontline starting pitcher and a first baseman are the main priorities for Boston, but it's clear another position to needs to be upgraded for the second consecutive summer. BOSTON, MASSACHUSETTS - JULY 2: Connor Wong #12 of the Boston Red Sox hits a single during the second inning of a game against the Cincinnati Reds on July 2, 2025 at Fenway Park in... BOSTON, MASSACHUSETTS - JULY 2: Connor Wong #12 of the Boston Red Sox hits a single during the second inning of a game against the Cincinnati Reds on July 2, 2025 at Fenway Park in Boston, Massachusetts. More Photo by Maddie Malhotra/Boston/Getty Images Boston moved on from backup catcher Reese McGuire last summer and traded for Toronto Blue Jays catcher Danny Jansen to pair with Connor Wong, who found a surge in his bat. This year, Carlos Narvaez outplayed Wong to win the starting job following an offseason trade with the New York Yankees. Narvaez continues to pace MLB backstops in runners caught stealing and defensive runs saved, though he's manned a heavy workload through the first 100 games of the season. The Red Sox have gotten next to nothing from Wong, who is yet to deliver a hit with runners in scoring position. He has just one run driven in this season to the tune of a .372 OPS. It won't take much for Boston to earn an upgrade and the market isn't loaded. If the chance comes around, for the sake of Narvaez's help, the Red Sox need to be proactive behind the plate. More MLB: Yankees Have Competition From 11 Teams For All-Star Third Baseman: Report

What former Boston Celtics guard Jrue Holiday, Damian Lillard were really talking about
What former Boston Celtics guard Jrue Holiday, Damian Lillard were really talking about

USA Today

time22 minutes ago

  • USA Today

What former Boston Celtics guard Jrue Holiday, Damian Lillard were really talking about

Portland Trail Blazers floor general Damian Lillard and former Boston Celtics (and now Portland) point guard Jrue Holiday will forever be connected in how Holiday ended up being moved to the Celtics by way of the Blazers to make the failed Milwaukee Bucks - Dame experiment happen, only to add another title to Holiday's resume with Boston. But it turns out that the two ironic Trail Blazers teammates of the present also share some surprising if a bit mundane history many thought might have been some sort of conspiratorial talk when the pair were seen on the court last season chatting about some unknown topic. It turns out it is the same sort of conversation one tends to have in everyday life with whoever is in charge of a malfunctioning utility -- if with some extraordinary participants. KOIN News Sports Anchor Brenna Greene caught up with Lillard at a recent media availability for Lillard as he returned to his home market, and Dame shed some light on an in-game chat that had sparked speculation as to what the duo had been talking about. "When I lived in Milwaukee, I rented his house for two years so we talked a lot," explained Lillard. "I was complaining to him about the Wi-Fi." "There's a clip online of like I shake his hand, we played them in Boston, we had an interaction and people were like, 'What (is going on there)?,' And we were literally talking about his Wi-Fi at his house," he added. Sometimes, it seems, a cigar is just a cigar -- and WiFi can be a pain even for NBA stars. Listen to "Havlicek Stole the Pod" on: Spotify: iTunes: YouTube:

Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics
Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics

Business Wire

time22 minutes ago

  • Business Wire

Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen's antibody discovery platforms through a strategic investment. In turn, Propeller will collaborate closely with Leveragen and gain access to Leveragen's full suite of proprietary antibody mouse models, including the Singularity Sapiens Mouse, the industry-leading fully human single-domain antibody discovery platform. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery, It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability." - Dr. David Shen, CEO of Propeller Bio Share The Singularity Sapiens Mouse is engineered to produce robust immune responses across a broad range of antigens, enabling efficient discovery of fully human VH-only antibodies with strong developability and diverse epitope coverage. The platform supports multiple therapeutic formats, including bispecifics, antibody-drug conjugates, CAR-T therapies, and mRNA-encoded antibodies, making it a versatile tool for biologics development. 'We're excited to collaborate with Dr. David Shen and the team at Propeller Bio,' said Weisheng Chen, PhD, Founder and CEO of Leveragen. 'David has a remarkable track record of bringing innovative biomedicines to patients in need. We believe Propeller Bio is well positioned to lead the next wave of therapeutic breakthroughs, and we're proud to support their work with our cutting-edge antibody discovery platforms.' David W. Shen, PhD, Founder and CEO of Propeller Bio, is a widely recognized leader in antibody and protein therapeutics. He previously held senior leadership roles at Amgen, Merck, Teva, and NGM Bio. Most recently, he was Founder and CEO of Proteologix, a leader in the development of bispecific antibodies for immune-mediated diseases. In less than three years since inception, the company was acquired by Johnson & Johnson for $850 million upfront and an undisclosed milestone payment in 2024. 'Leveragen's Singularity Sapiens Mouse is a differentiated platform for antibody discovery,' said Dr. Shen. 'It provides a unique option for high-quality, in vivo matured human VH domains with impressive diversity and developability. This platform presents a compelling alternative to camelid immunization or synthetic libraries, offering speed, flexibility, and translational relevance. It gives us a solid foundation for building a differentiated pipeline.' This collaboration highlights Leveragen's growing role as a trusted discovery partner for biotech companies pushing the frontiers of biologics innovation. About Leveragen Leveragen is a biotech company based in Woburn, Massachusetts, focused on accelerating biologics innovation through next-generation in vivo discovery platforms. Its Singularity Suite includes a collection of genetically engineered mouse models capable of generating exclusively single-domain antibodies from the VH repertoires of humans, mice, and companion animals. These platforms support the development of advanced therapeutic modalities, including bispecifics, ADCs, mRNA-encoded antibodies, targeted drug delivery, and cell therapies. Leveragen's technologies are trusted by leading biotech and pharmaceutical companies around the world. LinkedIn About Propeller Bio Propeller Bio is founded by David Shen along with a group of seasoned biotech entrepreneurs with a proven track record of success. Supported by leading investors, the company focuses on discovering and developing innovative biologic therapeutics designed to safely and effectively target multiple disease-driving pathways, aiming for synergistic effects to treat patients with unmet medical needs. The organization boasts a diverse team with extensive expertise in drug discovery and development, and is based in the Bay Area, California.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store